BibTex format

author = {Visca, D and Mori, L and Tsipouri, V and Fleming, S and Firouzi, A and Bonini, M and Pavitt, MJ and Alfieri, V and Canu, S and Bonifazi, M and Boccabella, C and De, Lauretis A and Stock, CJW and Saunders, P and Montgomery, A and Hogben, C and Stockford, A and Pittet, M and Brown, J and Chua, F and George, PM and Molyneaux, PL and Margaritopoulos, GA and Kokosi, M and Kouranos, V and Russell, AM and Birring, SS and Chetta, A and Maher, TM and Cullinan, P and Hopkinson, NS and Banya, W and Whitty, JA and Adamali, H and Spencer, LG and Farquhar, M and Sestini, P and Wells, AU and Renzoni, EA},
doi = {10.1016/S2213-2600(18)30289-3},
journal = {Lancet Respiratory Medicine},
pages = {759--770},
title = {Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial},
url = {},
volume = {6},
year = {2018}

RIS format (EndNote, RefMan)

AB - BACKGROUND: In fibrotic interstitial lung diseases, exertional breathlessness is strongly linked to health-related quality of life (HRQOL). Breathlessness is often associated with oxygen desaturation, but few data about the use of ambulatory oxygen in patients with fibrotic interstitial lung disease are available. We aimed to assess the effects of ambulatory oxygen on HRQOL in patients with interstitial lung disease with isolated exertional hypoxia. METHODS: AmbOx was a prospective, open-label, mixed-method, crossover randomised controlled clinical trial done at three centres for interstitial lung disease in the UK. Eligible patients were aged 18 years or older, had fibrotic interstitial lung disease, were not hypoxic at rest but had a fall in transcutaneous arterial oxygen saturation to 88% or less on a screening visit 6-min walk test (6MWT), and had self-reported stable respiratory symptoms in the previous 2 weeks. Participants were randomly assigned (1:1) to either oxygen treatment or no oxygen treatment for 2 weeks, followed by crossover for another 2 weeks. Randomisation was by a computer-generated sequence of treatments randomly permuted in blocks of constant size (fixed size of ten). The primary outcome, which was assessed by intention to treat, was the change in total score on the King's Brief Interstitial Lung Disease questionnaire (K-BILD) after 2 weeks on oxygen compared with 2 weeks of no treatment. General linear models with treatment sequence as a fixed effect were used for analysis. Patient views were explored through semi-structured topic-guided interviews in a subgroup of participants. This study was registered with, number NCT02286063, and is closed to new participants with all follow-up completed. FINDINGS: Between Sept 10, 2014, and Oct 5, 2016, 84 patients were randomly assigned, 41 randomised to ambulatory oxygen first and 43 to no oxygen. 76 participants completed the trial. Compared with no oxygen, ambulatory oxygen was ass
AU - Visca,D
AU - Mori,L
AU - Tsipouri,V
AU - Fleming,S
AU - Firouzi,A
AU - Bonini,M
AU - Pavitt,MJ
AU - Alfieri,V
AU - Canu,S
AU - Bonifazi,M
AU - Boccabella,C
AU - De,Lauretis A
AU - Stock,CJW
AU - Saunders,P
AU - Montgomery,A
AU - Hogben,C
AU - Stockford,A
AU - Pittet,M
AU - Brown,J
AU - Chua,F
AU - George,PM
AU - Molyneaux,PL
AU - Margaritopoulos,GA
AU - Kokosi,M
AU - Kouranos,V
AU - Russell,AM
AU - Birring,SS
AU - Chetta,A
AU - Maher,TM
AU - Cullinan,P
AU - Hopkinson,NS
AU - Banya,W
AU - Whitty,JA
AU - Adamali,H
AU - Spencer,LG
AU - Farquhar,M
AU - Sestini,P
AU - Wells,AU
AU - Renzoni,EA
DO - 10.1016/S2213-2600(18)30289-3
EP - 770
PY - 2018///
SN - 2213-2600
SP - 759
TI - Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial
T2 - Lancet Respiratory Medicine
UR -
UR -
UR -
VL - 6
ER -